BioAtla
BCAB
62 hedge funds and large institutions have $964M invested in BioAtla in 2021 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 22 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
82% more capital invested
Capital invested by funds: $530M → $964M (+$434M)
41% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 22
17% more funds holding
Funds holding: 53 → 62 (+9)
0.21% more ownership
Funds ownership: 0.97% → 1.18% (+0.21%)
8% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$118M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$47.6M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$47M |
| 4 |
BlackRock
New York
|
+$42.1M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$24.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$21.7M |
| 3 |
Millennium Management
New York
|
-$15.3M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$14.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$5.2M |
BCAB Hedge Fund Activity: Q1 2021 in Review
62 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in BioAtla (BCAB) for Q1 2021, worth a combined $964M — up 82% from $530M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new BCAB positions and 22 closed out — a net gain of 9 holders — while 11 added to existing stakes and 12 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $118M. The largest seller was Farallon Capital Management, cutting an estimated $24.4M.
- 62 institutional investors held BioAtla (BCAB) as of Q1 2021, up from 53 in Q4 2020.
- Funds reported $964M of BioAtla stock for Q1 2021, up 82% quarter-over-quarter.
- 31 funds opened new BioAtla positions in Q1 2021 and 22 closed out, a net change of +9 holders.
- The largest BioAtla buyer in Q1 2021 was Fidelity Investments, an estimated $118M added.
- The largest BioAtla seller in Q1 2021 was Farallon Capital Management, an estimated $24.4M sold.
Based on aggregated 13F filings for Q1 2021.